Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Volavka

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
The Journal of Neuropsychiatry and Clinical Neurosciences|December 1, 2006
Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorderMatthew J Hoptman, Jan Volavka, Pál Czobor, et al.
The British Journal of Psychiatry : the Journal of Mental Science|August 14, 2008
Comparison of antipsychotic medication effects on reducing violence in people with schizophreniaJeffrey W Swanson, Marvin S Swartz, Richard A Van Dorn, et al.
Human Psychopharmacology|August 9, 2011
Genetic interactions in the adrenergic system genes: analysis of antipsychotic-induced weight gainVincenzo De Luca, Renan P Souza, Emanuela Viggiano, et al.
The Journal of Clinical Psychiatry|June 6, 2009
Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior responseJean-Pierre Lindenmayer, Hong Liu-Seifert, Pandurang M Kulkarni, et al.
Psychiatry Research|October 29, 2005
Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorderMatthew J Hoptman, Jan Volavka, Elisabeth M Weiss, et al.
Pharmacological Research|February 3, 2005
Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatmentVincenzo De Luca, John B Vincent, Daniel J Müller, et al.
The American Journal of Psychiatry|June 4, 2002
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorderRobert M Bilder, Robert S Goldman, Jan Volavka, et al.
Neuroscience Letters|April 13, 2005
The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophreniaDaniel J Müller, Tim A Klempan, Vincenzo De Luca, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 6, 2005
Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophreniaDaniel J Müller, Vincenzo De Luca, Tricia Sicard, et al.
Journal of Clinical Psychopharmacology|July 16, 2008
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose studyBruce J Kinon, Jan Volavka, Virginia Stauffer, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
The Journal of Neuropsychiatry and Clinical Neurosciences|December 1, 2006
Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorderMatthew J Hoptman, Jan Volavka, Pál Czobor, et al.
The British Journal of Psychiatry : the Journal of Mental Science|August 14, 2008
Comparison of antipsychotic medication effects on reducing violence in people with schizophreniaJeffrey W Swanson, Marvin S Swartz, Richard A Van Dorn, et al.
Human Psychopharmacology|August 9, 2011
Genetic interactions in the adrenergic system genes: analysis of antipsychotic-induced weight gainVincenzo De Luca, Renan P Souza, Emanuela Viggiano, et al.
The Journal of Clinical Psychiatry|June 6, 2009
Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior responseJean-Pierre Lindenmayer, Hong Liu-Seifert, Pandurang M Kulkarni, et al.
Psychiatry Research|October 29, 2005
Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorderMatthew J Hoptman, Jan Volavka, Elisabeth M Weiss, et al.
Pharmacological Research|February 3, 2005
Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatmentVincenzo De Luca, John B Vincent, Daniel J Müller, et al.
The American Journal of Psychiatry|June 4, 2002
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorderRobert M Bilder, Robert S Goldman, Jan Volavka, et al.
Neuroscience Letters|April 13, 2005
The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophreniaDaniel J Müller, Tim A Klempan, Vincenzo De Luca, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 6, 2005
Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophreniaDaniel J Müller, Vincenzo De Luca, Tricia Sicard, et al.
Journal of Clinical Psychopharmacology|July 16, 2008
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose studyBruce J Kinon, Jan Volavka, Virginia Stauffer, et al.
Pageof 10